Navigation Links
Second Genome Announces Agreement with Janssen on Microbiome Drug Discovery in Ulcerative Colitis
Date:6/5/2013

SAN BRUNO, Calif., June 5, 2013 /PRNewswire/ -- Second Genome, Inc. announced today that the company has entered into an agreement with Janssen Biotech, Inc. (Janssen) focused on microbiome drug discovery. With the goal of advancing novel drug targets, the agreement is focused on therapeutic mechanisms in ulcerative colitis mediated by the bacterial ecosystem living within the human gut, referred to as the microbiome. Second Genome will apply its microbiome modulation discovery platform to characterize the role of bacterial populations in ulcerative colitis.  

"Foundational microbiome research over the past several years has demonstrated that alterations to the microbiome are central to the development of inflammation and metabolic disorders," said Peter DiLaura, President and CEO at Second Genome. "The role of the microbiome in health and disease has arrived as a significant area of focus in pharmaceutical R&D. This collaboration with Janssen will identify mechanisms by which microbial populations in the gut have an impact in ulcerative colitis."

Under the terms of the agreement, Second Genome will receive an upfront payment and support for research activities conducted by Second Genome in collaboration with Janssen. In addition, Second Genome is eligible to receive potential payments upon the achievement of certain research milestones. The research will be funded through the Johnson & Johnson Innovation Center and the Immunology Therapeutic Area within Janssen Research & Development, LLC.

The human microbiome is the population of more than 100 trillion microorganisms that live in our gut, mouth, skin and elsewhere in and on the body. These microbial communities play critical roles in supporting life and health. They are needed to digest food, to prevent disease-causing bacteria from invading the body, and to synthesize essential nutrients and vitamins. Pioneering a path for translating microbiome discoveries into novel therapeutics, Second Genome has developed a proprietary approach for generating therapeutic candidates that modulate microbe-microbe and microbe-human interactions that contribute to health and disease.

"A breakdown in the normal relationship between the human immune system and the bacterial communities that reside in the gut appears to play an important role in development of the hallmark chronic inflammation of ulcerative colitis," said Dr. Susan Lynch , scientific advisor to Second Genome and Director of the Colitis and Crohn's Disease Microbiome Research Core and Associate Professor, Gastroenterology at University of California, San Francisco.  "Second Genome has a powerful platform to mine the microbiome for potential targets which have the potential to translate into effective therapeutics that dramatically impact patient health."

Series A Financing and Board Appointments

Separately, Second Genome announced today it has received an additional $6.5 million in Series A financing, bringing the total amount raised in the Series A round to $11.5 million.  Current investors participated in the financing, including Advanced Technology Ventures, Morgenthaler, and Wavepoint Ventures, and individuals including Dr. Corey Goodman , co-founder and Chair of the Board of Directors, and Dr. Matt Winkler , also on the Board of Directors. The new funding will be used to accelerate programs in metabolic disease, inflammation, and infection.

Second Genome also announced the appointment of Brad A. Margus , former CEO and co-founder of Envoy Therapeutics, to its board of directors; and Jerrold M. Olefsky , Professor of Medicine at the University of California, San Diego to its scientific advisory board.

Mr. Margus co-founded Envoy Therapeutics Inc. in 2009, serving as Chief Executive Officer prior to its acquisition by Takeda Pharmaceutical Company in 2012. Earlier, Mr. Margus co-founded Perlegen Sciences, Inc. and served as its Vice Chairman and Chief Executive Officer. Mr. Margus has been a member of numerous IRBs, NIH advisory committees and corporate boards.  He currently serves as Chairman and volunteer President of the A-T Children's Project; as a Harvard Business School Global Advisor; on the Board of Children's Neurobiological Solutions, an organization aimed at applying brain repair and regeneration to pediatric neurological disorders; as an advisor to the Rare Disease Network; and as Co-chair of the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) External Oversight Board.

Dr. Olefsky is Professor of Medicine at the University of California, San Diego (UCSD) Division of Endocrinology and Metabolism and the Associate Dean of Scientific Affairs for the UCSD School of Medicine. His work has been instrumental in defining the basic genetic and cellular mechanisms responsible for the pathogenesis of Type II Diabetes, metabolic syndrome, and other diseases. Dr. Olefsky is a member of the Institute of Medicine and was the 1998 recipient of the American Diabetes Association's Banting Medal for Scientific Achievement. He currently serves on the scientific advisory boards of NGM Biopharmaceuticals, Metabolex, and the Profil Institute.

About Second Genome

Second Genome brings microbiome science to the discovery and development of therapeutic products. The company has established a pipeline of microbiome modulators that impact infection, inflammation, and metabolic diseases. Second Genome's development pipeline is fueled by novel technologies for identifying, screening and scientifically validating therapeutic candidates.  Please visit www.secondgenome.com for more information.


'/>"/>
SOURCE Second Genome, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response, Tolerability in Management of Anemia Secondary to Chemotherapy
2. MGC Diagnostics Corporation Reports 2013 Second Quarter Operating Results
3. Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference
4. MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013
5. MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference
6. Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference
7. Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference
8. Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference
9. American Pacific Reports Fiscal 2013 Second Quarter Results; Increases Full Year Guidance
10. NxStage Announces Second Quarter 2013 Investor Conference Schedule
11. Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... 2016  The Addiction Treatment Advisory Group (ATAG), ... Care Pharmacy (AMCP), has released detailed findings on ... opioid addiction crisis, including through improved access to ... ATAG,s newly released paper, "The Role of Managed ... many issues around gaps and barriers to addiction ...
(Date:12/2/2016)... Dec. 2, 2016 Boston Scientific Corporation (NYSE: ... to acquire certain manufacturing assets and capabilities of the ... advanced biological tissue business, as well as a 15% ... million in cash. The Neovasc advanced biological tissue business ... Boston Scientific Lotus™ Valve System. * Upon completion ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional ... Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to extend ... , The demand for supplemental training related to pain management has surged dramatically ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a ... No other wearable health technology on the market can deliver all that rejiva can. ... meaningful insights about their health than the usual heart rate and steps taken”, adds ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... & Author of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein ... Hour Power of Water, Global Climate Change and Your Health radio program syndicated ...
(Date:11/30/2016)... CA (PRWEB) , ... November 30, 2016 , ... ... announce that they now offer a comprehensive in-house dental plan for all patients. ... have developed a plan that gives patients a number of perks, including discounts ...
Breaking Medicine News(10 mins):